Liestal, Switzerland

Judith Schaefer

This inventor holds 2 USPTO granted patents. Top assignee: Novartis Ag. Active years: 2011-2012.


Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2011-2012

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Judith Schaefer: Innovator in Drug Monitoring Assays

Introduction

Judith Schaefer is a prominent inventor based in Liestal, Switzerland. She has made significant contributions to the field of pharmaceutical sciences, particularly in the development of drug monitoring assays. With a total of 2 patents to her name, her work has the potential to enhance the efficacy and safety of pharmaceutical treatments.

Latest Patents

Judith's latest patents focus on a method for obtaining binding agents that specifically target pharmaceutically active forms of compounds. This method utilizes special derivatives of the parent compound to achieve higher specificity compared to pharmaceutically inactive forms. The inventions also include the respective binding agents and derivatives, along with drug monitoring assays that utilize these agents for monitoring active forms of the parent compound.

Career Highlights

Judith Schaefer is currently associated with Novartis AG, a leading global healthcare company. Her role at Novartis allows her to work on innovative solutions that address critical healthcare challenges. Her expertise in drug monitoring assays positions her as a key player in the pharmaceutical industry.

Collaborations

Judith collaborates with notable colleagues such as Patrick Albientz and Francois Legay. These partnerships enhance her research and development efforts, contributing to the advancement of pharmaceutical technologies.

Conclusion

Judith Schaefer's work in drug monitoring assays exemplifies her commitment to innovation in the pharmaceutical field. Her contributions are paving the way for more effective and safer drug therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…